PetMed Express, Inc. (NASDAQ:PETS)
Q2 2016 Earnings Conference Call
October 24, 2016 08:30 AM ET
Bruce Rosenbloom - CFO
Menderes Akdag - President and CEO
Welcome to the PetMed Express Incorporated doing business as 1-800-PetMeds conference call to review the financial results for the second fiscal quarter that ended on September 30, 2016. At the request of the company, this conference call is being recorded.
Founded in 1996, 1-800-PetMeds is America’s largest pet pharmacy delivering prescription and non-prescription pet medications and other health products for dogs and cats direct to the customer. 1-800-PetMeds markets its products through national television, online, direct mail and print advertising campaigns, which direct customers to order by phone or through Internet and aim to increase the recognition of the PetMed’s family and brand names. 1-800-PetMeds provides an attractive alternative for obtaining pet medications in terms of convenience, price, ease of ordering, and rapid home delivery.
At this time, I would like to turn the call over to the Company’s Chief Financial Officer, Mr. Bruce Rosenbloom. Sir, you may now begin.
Thank you. I’d like to welcome everybody here today. Before I turn the call over to Menderes Akdag, our President and Chief Executive Officer, I would like to remind everyone that the first portion of this conference call will be listen-only until the question-and-answer session which will be later in the call.
Also, certain information that will be included in this press conference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or the Securities and Exchange Commission that may involve a number of risks and uncertainties. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements may involve risks, uncertainties, and assumptions.
Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We’ve identified various risk factors associated with our operations in our most recent annual report and other filings with the Securities and Exchange Commission.
Now let me introduce today’s speaker, Menderes Akdag, the President and Chief Executive Officer of 1-800-PetMeds. Mendo?
Thank you, Bruce. Welcome everyone and thank you for joining us. Today, we will review the highlights of our financial results. We’ll compare our second fiscal quarter and six months ended on September 30, 2016 to last year’s quarter and six months ended on September 30, 2015.
For the second fiscal quarter ended on September 30, 2016, sales were $60.8 million compared to $56.7 million for the same period the prior year, an increase of 7.2%. For the six months ended on September 30, 2016, sales were $133.3 million, compared to $128.4 million for the six months the prior year, an increase of 3.8%. The increases in sales were due to increases in new order and reorder sales.
The average order value was approximately $82 for the quarter compared to $80 for the same period last year. For the second fiscal quarter, net income was $4.9 million or $0.24 diluted per share compared to $4.5 million or $0.22 diluted per share for the same quarter as the prior year, an increase to net income of 8.8%. And for the six months, net income was $11.5 million or $0.56 diluted per share compared to $10.3 million or $0.51 diluted per share a year ago, an increase to net income of 12%.
Reorder sales increased by 7.4% to $50.1 million for the quarter, compared to reorder sales of $46.7 million for the same quarter the prior year. For the six months, the reorder sales increased by 2.9% to $109.3 million compared to $106.2 million for the same period last year.
New order sales increased by 6.3% to $10.7 million for the quarter compared to $10.1 million for the same period the prior year. For the six months, the new order sales increased by 8.5% to $24 million compared to $22.1 million for the same period last year. We acquired approximately 131,000 new customers in our second fiscal quarter compared to 127,000 for the same period the prior year. And we acquired approximately 289,000 new customers in the six months compared to 275,000 for the same period a year ago. Approximately 82% of our sales were generated on our website for the quarter compared to 81% for the same period the prior year. The seasonality in our business is due to the proportion of flea, tick and heartworm medications in our product mix. Spring and summer are considered peak seasons with fall and winter being the offseason.
For the second fiscal quarter, our gross profit as a percent of sales was 29.7% compared to 33.3% for the same period the prior year. And for the six months, our gross profit as a percent of sales was 30.4% compared to 32.6% for the same period a year ago. The percentage decrease was due to additional discounts given to customers to increase sales. Our general and administrative expenses as a percent of sales were relatively flat for the quarter compared to the same quarter last year and it was slightly up for the six months. For the quarter, we spent $4.4 million in advertising compared to $6.2 million for the same quarter the prior year. For the six months, we spent $10.1 million in advertising compared to $14.1 million during the same period a year ago. The advertising cost of acquiring a customer was approximately $33 for the quarter compared to $49 for the same quarter the prior year. And for the six months, it was $35 compared to $51 for the six months the prior year. We were much more efficient compared to last year. We had $51.9 million in cash and cash equivalents, $14.8 million in inventory with no debt as of September 30, 2016. Net cash from operations for the six months was $27.8 million compared to $14 million for the same period last year. The increase was mainly due to decreases in inventory.
This ends the financial review, operator we are ready to take questions.
Our first question comes from Irwin Wilson from Credit Suisse. Your line is now open. I'm sorry, the line got disconnected. As of the moment speakers, we show no questions on queue.
Okay thank you. We’re currently preparing to move into our new corporate headquarters and distribution center, which is expected to occur in this quarter. This wraps up today’s conference call, thank you for joining us. Operator this ends the conference call.
Thank you for your participation, you may now disconnect.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: email@example.com. Thank you!